Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Senaparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Senaparib overview

Senaparib is under development for the treatment of solid tumours including small cell lung cancer, metastatic castration-resistant prostate cancer (mCRPC), ovarian cancer, fallopian tube cancer, epithelial ovarian cancer, peritoneal cancer, lung cancer and breast cancer. The drug candidate targets PARP (Poly(ADP-ribose) polymerase). The drug candidate was also under development for melanoma, prostate cancer and liver cancer. It is administered through oral route.

IMPACT Therapeutics overview

IMPACT Therapeutics (IMPACT) is a biopharmaceutical company that develops anti-cancer therapeutics based on synthetic lethality. The company pipeline products include PARP inhibitor (Senaparib/ IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064) PARP1 selective inhibitor (IMP1734) and other novel DDR pathway inhibitors. Senaparib/IMP4297, a PARP inhibitor, is being tested in Phase II/III trials for the treatment of small cell lung cancer, ovarian cancer and others. IMPACT is headquartered in Nanjing, China.

For a complete picture of Senaparib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.